In general, the results suggest considerable overlap between paranoid ideation, predisposition to hallucinations, and OCD and metacognitive beliefs in a non-clinical sample. Further experimental- and clinical studies are needed in order to explore metacognitive models of OCD and psychosis.
We report a case of a patient experiencing wearing-off symptoms with aripiprazole LAI who benefited from switching to aripiprazole lauroxil. Pharmacogenetic testing revealed normal activity for relevant metabolism pathways but a DRD2 -141C variant that may influence brain D2 expression and antipsychotic responsiveness.
Antipsychotics may possess immunological properties that may be involved in immune-mediated conditions, such as psoriatic rash. Further studies are warranted to determine causality and mechanism.
The therapeutic benefits achieved by the extended, 3-year early intervention were not sustainable after termination of the specialised service. To read the full article, log in using your SSSFT NHS OpenAthens details
Patients with schizophrenia are at a significantly increased risk of cancer mortality compared with the general population or individuals without schizophrenia. To read the full article, log in using your SSSFT NHS OpenAthens details
Many people with schizophrenia do not achieve a satisfactory treatment response with their initial antipsychotic drug treatment. Sometimes a second antipsychotic, in combination with the first, is used in these situations.
Living in a city could make young people more vulnerable to psychotic experiences, according to a UK study.
To read the full article, log in using your SSSFT NHS OpenAthens details
Laoise Renwick on a systematic review of barriers and facilitators to implementing family support and education in early psychosis intervention programmes.
Antipsychotic drug sensitivity in very late-onset schizophrenia-like psychosis (VLOSLP) is well documented, but poorly understood. This study aimed to investigate blood drug concentration, D2/3 receptor occupancy and outcome in VLOSLP during open amisulpride prescribing, and compare this with Alzheimer's disease (AD). Login using your SSSFT NHS OpenAthens details for full text.
Objectives To evaluate the usability of a neuropsychological screening instrument and two observation scales of everyday behaviour to describe cognitive and functional capacity of patients with multiepisode schizophrenia and considerable care needs, who frequently refuse to participate in cognitive testing or performance-based functional measurement.
Open Access Article
Schizophrenia is a neurological disease characterized by alterations to patients’ cognitive functions and emotional expressions. Relevant studies often use magnetic resonance imaging (MRI) of the brain to explore structural differences and responsiveness within brain regions. However, as this technique is expensive and commonly induces claustrophobia, it is frequently refused by patients. Thus, this study used non-contact infrared thermal facial images (ITFIs) to analyze facial temperature changes evoked by different emotions in moderately and markedly ill schizophrenia patients.
The study examined six-month follow-up results and the impact of length of illness on treatment outcomes of recovery-oriented cognitive therapy (CT-R). Login at top right hand side of page using your SSSFT NHS Athens for full text.
Safety-seeking behaviours are responses employed to protect against perceived threat. In relation to anxiety disorders, safety-seeking behaviours have been implicated in both the formation and maintenance of distress. Several studies have highlighted similar findings in relation to psychosis; however, this literature has not yet been synthesized. This review is, therefore, being conducted in order to synthesize the literature on safety seeking in people with psychosis to increase the understanding of this relationship. Login using your SSSFT NHS OpenAthens details for full text.
We’ve just heard that SSOTP will not be renewing their agreement with SSSFT LKS for library services for this financial year. Because of this we will be reviewing our Be Aware bulletins. Sadly we won’t be accepting any new sign-ups from SSOTP staff and will be withdrawing some of the physical healthcare bulletins that we…
People with schizophrenia who are treated with long acting injectable antipsychotics have a 20-30% lower risk of relapse requiring readmission to hospital than people treated with equivalent oral formulations, a nationwide study assessing the real world effectiveness of these drugs has found.
To read the full article, log in using your SSSFT NHS OpenAthens details
Randomized controlled trials in adults with severe mental illness indicate that, compared with standard care, intensive case management (ICM) improves retention in treatment and may reduce hospitalization but other positive effects of ICM are unclear.
Open access. The majority of patients respond to antipsychotic monotherapy at standard doses, but a subset of patients will require more heroic measures that include antipsychotic polypharmacy and high-dose monotherapy. Indeed, research has shown that roughly 30% of patients with psychosis are prescribed multiple antipsychotic medications. We discuss the potential benefits and challenges of these approaches and provide a rationale for why and when they should be utilised.
Open access. The STEPWISE trial (STructured lifestyle Education for People WIth SchizophrEnia, schizoaffective disorder and first episode psychosis) is currently evaluating a lifestyle education programme in addition to usual care. However, it is difficult to define what constitutes ‘usual care’. We aimed to define ‘usual care’ for lifestyle management in people with schizophrenia, schizoaffective disorder and first-episode psychosis in STEPWISE study sites. Ten National Health Service (NHS) mental health trusts participated in a bespoke survey based on the National Institute for Health and Care Excellence (NICE) guidance.
Lithium is the third element in the periodic table, and although lithium is present in the natural environment and is used to make batteries, it is perhaps best known as a therapeutic drug. Lithium in various forms was used to treat neuropsychiatric disorders before falling into disuse because of concerns over toxicity. The Australian psychiatrist John Cade rediscovered lithium for the treatment of mania in 1949 and the Danish psychiatrist Mogens Schou did one of the first randomised controlled trials in mania in 1954 assessing lithium use, also suggesting the potential for use of lithium as a prophylactic drug for depressive illness. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai